Auron Therapeutics, Inc.

Auron Therapeutics is a biotechnology company focused on developing next-generation targeted therapies for solid tumors and hematological malignancies by identifying and inhibiting the dysregulated cell states of cancer. The company's proprietary AURIGIN platform utilizes AI and machine learning to compare normal cell states with cancerous cell states, allowing Auron to identify novel cancer targets, optimal development models, and biomarkers for patient selection. Auron has assembled a team of experts in cancer biology, medicinal chemistry, and computational science who work closely with leading physician-scientists.

Auron's lead product candidate, AUTX-703, is an orally available, potent, and selective small molecule degrader of KAT2A/B, a histone acetyltransferase identified by AURIGIN and associated with multiple tumor types. Auron is currently developing AUTX-703 for the treatment of small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia. The company is committed to delivering transformational therapies for patients in need by leveraging its innovative platform and team of experts.

Auron Therapeutics embraces a flexible, hybrid work environment, offering unlimited PTO to allow employees to manage their personal and professional commitments with greater enjoyment and less stress. The company provides a robust benefits package, including medical, dental, and vision coverage with a Blue Cross Blue Shield PPO HSA plan that has a deductible 100% covered by Auron, as well as paid parental leave, life, travel and AD&D insurance, and a 401(K) plan.

Auron Therapeutics offers a competitive benefits package that includes unlimited paid time off, medical, dental, and vision coverage with a Blue Cross Blue Shield PPO HSA plan that has a deductible 100% covered by Auron, paid parental leave, life, travel and AD&D insurance, and a 401(K) plan. The company also embraces a flexible, hybrid work environment, promoting employee well-being and work-life balance.

Auron Therapeutics is a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer. They aim to transform the treatment of solid tumors and hematological malignancies, offering patients longer, higher quality lives. Their approach involves mapping cancer cell development against normal cell development using a proprietary AI-powered platform called AURIGIN™, which identifies and targets the drivers of tumorigenesis to revert cancer cells to a normal state and inhibit their growth and proliferation.

Auron Therapeutics promotes a culture of curiosity, strategic and creative thinking, and a relentless pursuit of pushing the boundaries of science. They value diversity and individuality, fostering a collaborative environment where every voice matters. Their commitment to serving patients and families is at the heart of their culture, and they strive to provide a supportive work environment that prioritizes employee growth and well-being.

Auron Therapeutics fosters a culture that values diversity and individuality. They promote a workplace where everyone feels welcome and respected, encouraging curiosity, strategic thinking, and creativity. They are united by a single commitment to serving patients and families in need of new treatments, and their mission reflects a dedication to creating an inclusive and equitable environment where all team members can thrive.